125 related articles for article (PubMed ID: 6132266)
1. Oxyquinoline neurotoxicity.
Guy-Grand B; Basdevant A; Soffer M
Lancet; 1983 Apr; 1(8331):933. PubMed ID: 6132266
[No Abstract] [Full Text] [Related]
2. [SMON].
Paal G
MMW Munch Med Wochenschr; 1976 Dec; 118(51):suppl [7]-[8]. PubMed ID: 826814
[No Abstract] [Full Text] [Related]
3. [SMON syndrome. First case after abuse of a methylated hydroxyquinoline derivative].
Saragoussi JJ; Soffer M; Giraud D; Raison J; Basdevant A; Pouliquen Y
Bull Soc Ophtalmol Fr; 1984 Jan; 84(1):25-8. PubMed ID: 6442219
[No Abstract] [Full Text] [Related]
4. Oxyquinoline toxicity.
Soffer M; Basdevant A; Sarragoussi JJ; Raison J; Guy-Grand B
Lancet; 1983 Mar; 1(8326 Pt 1):709. PubMed ID: 6132067
[No Abstract] [Full Text] [Related]
5. Toxicity of oxyquinolines.
Hansson O
Lancet; 1977 May; 1(8022):1152. PubMed ID: 68247
[No Abstract] [Full Text] [Related]
6. More on S.M.O.N.
Lancet; 1971 Dec; 2(7736):1244. PubMed ID: 4143604
[No Abstract] [Full Text] [Related]
7. [SMON outside Japan--a neurologic evaluation].
Silfverskiöld B
Lakartidningen; 1980 May; 77(19):1821-2. PubMed ID: 7392712
[No Abstract] [Full Text] [Related]
8. Ethnic differences in drugs and xenobiotics. Clioquinol.
Rose FC
Prog Clin Biol Res; 1986; 214():323-30. PubMed ID: 2941765
[No Abstract] [Full Text] [Related]
9. [Hydroxyquinoline victims in Sweden].
Hansson O
Lakartidningen; 1978 Sep; 75(36):3064-7. PubMed ID: 682760
[No Abstract] [Full Text] [Related]
10. [Subacute myelo-optico-neuropathy].
Hallen O
Nervenarzt; 1980 Apr; 51(4):242-5. PubMed ID: 6775237
[No Abstract] [Full Text] [Related]
11. Zinc deficiency, acrodermatitis enteropathica, optic atrophy, subacute myelo-optic neuropathy, and 5,7-dihalo-8-quinolinols.
Sturtevant FM
Pediatrics; 1980 Mar; 65(3):610-3. PubMed ID: 6444713
[TBL] [Abstract][Full Text] [Related]
12. Chinese acupuncture treatment for SMON patients.
Katahira K; Kobayshi T; Higashida T; Kamae S; Nakajima Y; Fujimoto S
Chin Med J (Engl); 1986 Nov; 99(11):910-1. PubMed ID: 2953563
[No Abstract] [Full Text] [Related]
13. Assessment of neurotoxicity of clioquinol (Enterovioform) by visual evoked potentials. A preliminary communication.
Bhasin DK; Raina R; Mehta SK; Arora MM
Indian J Gastroenterol; 1985 Jul; 4(3):165-6. PubMed ID: 3160659
[No Abstract] [Full Text] [Related]
14. The aetiology of SMON may involve an interaction between clioquinol and environmental metals.
Tjälve H
Med Hypotheses; 1984 Nov; 15(3):293-9. PubMed ID: 6240588
[TBL] [Abstract][Full Text] [Related]
15. The neurotoxicity of the halogenated hydroxyquinolines. A commentary.
Oakley GP
JAMA; 1973 Jul; 225(4):395-7. PubMed ID: 4270059
[No Abstract] [Full Text] [Related]
16. [The history of quinolines].
Wolffers I
Ned Tijdschr Geneeskd; 1985 Jun; 129(26):1246-9. PubMed ID: 3160957
[No Abstract] [Full Text] [Related]
17. [Neurological complications in the course of treatment of acrodermatitis enteropathica with oxyquinoline derivatives].
Papuziński M; Wilmowska-Pietruszyńska A
Pediatr Pol; 1974 Nov; 49(11):1393-7. PubMed ID: 4278959
[No Abstract] [Full Text] [Related]
18. Subacute myelo-optic neuropathy and the halogenated hydroxyquinolines.
Med J Aust; 1971 Nov; 2(21):1090-1. PubMed ID: 5127493
[No Abstract] [Full Text] [Related]
19. [Neurotoxicity of chinoform].
Iwashita H
Ryoikibetsu Shokogun Shirizu; 1999; (27 Pt 2):602-5. PubMed ID: 10434730
[No Abstract] [Full Text] [Related]
20. Clioquinol.
Bernard G; Griffith RW
Lancet; 1977 Apr; 1(8018):956. PubMed ID: 67419
[No Abstract] [Full Text] [Related]
[Next] [New Search]